Thursday, December 19, 2019

Recent updates in hematology & oncology

Trials show, azacitidine & pembrolizumab combination is safe, feasible and well-tolerated for relapsed and refractory AML. Explore more trends in hematology & oncology at: hematology.cmesociety.com 
Posted by at
Labels: , , , , , , , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)